OneOncology

🥁 Chesapeake Oncology-Hematology Associates, P.A. joins Chesapeake Urology Associates on the OneOncology platform. 💪 Having COHA join CUA is testament to value created by bringing together urology and medical oncology practices onto OneOncology’s specialty medicine platform. CUA is an affiliate practice of United Urology Group, a specialty medicine management services organization supporting more than 250 providers. 💡 OneOncology says this partnership is part of its strategy to bring medical oncology and urology together at its partner practices to provide access to more integrated and holistic care in a high-quality and low-cost community setting. 🩺 Dr. Gayatri Nimmagadda, President, COHA said: "Having the ability to partner with leading specialty medical practices nationwide on the OneOncology platform means that more patients can receive cutting-edge quality care in their community at a lower cost and without the struggle of traveling to Baltimore or DC to see an excellent oncologist or hematologist." ⬇️ Read the news release. ⬇️ https://lnkd.in/ermy4QDC

🥁 Cancer Specialists of North Florida, a provider-owned oncology practice with 62 providers treating patients at 13 clinics, and OneOncology have finalized a partnership agreement that will enhance the delivery of cancer care services across the North Florida region. CSNF will be an anchor practice in Florida on the OneOncology platform. 🩺 CSNF will maintain its provider ownership and independence while also gaining access to OneOncology’s comprehensive platform of clinical, operational, and technological resources that support physician-led cancer care. 🐊 Marc Warmuth MD, President of CSNF: “Since 1983, we’ve been privileged to grow alongside the Northeast Florida community and care for our patients with compassion and innovation while keeping costs low and quality high. The OneOncology partnership will bring us capital, expertise, and solutions that will allow us to expand access to integrated health care services and continue meeting the needs of our patients and their families.” ⬇️ Read the release. https://lnkd.in/ew7AVzSw

A delegation of five physicians are visiting The Center for Cancer and Blood Disorders in Fort Worth Texas this week to learn about clinical and operational approached to cancer care. Dr. Bibas Reddy, President at The Center: “We deeply admire the resilience of Ukrainian physicians caring for their patients amid a war taking place within their own borders. We hope to share best practices and lessons from U.S. community oncology that can help support patient care during this conflict and as Ukrainians rebuild their medical infrastructure. One day soon, hopefully, when Ukraine is free, secure and in peace, we can come to Ukraine and we can continue to share knowledge." Read more about the Ukrainian physicians and their trip. ⬇️ https://lnkd.in/e6cUCCic

🥇 The OneOncology kickball team, OneBall (obviously), won the city kickball championship, 10-2, against their arch rivals - a team many had called a dynasty since they had not lost a game in 3 years. 🌃 But last night was different. 🔐 OneBall, which observers say was totally locked in, just took the champs to the wood shed. 🏆 This isn't OneBall's first taste from the championship cup. The team won the championship in 2022 -- and now has returned to the promised land. 🥇 Congratulations to all the teams in the league. And as we look forward to next year, we have one word for the rest of the league: REPEAT.

Early-phase cancer research represents the leading edge of cancer therapy innovation, testing how new drugs work in humans and determining safety and dosage. Today, Tennessee Oncology’s clinical research division – the GHCR - Greco-Hainsworth Centers for Research – is proud to open its new clinical research unit! Located inside our new flagship cancer center at Elliston Place Plaza in Nashville, the unit is led by Dr. Jeffery Russell and Dr. Joseph Merriman. Together, the two will oversee a team of 20 research professionals developing tomorrow's cancer treatments. To learn more about our new clinical research unit ⤵️ #TennesseeOncology #CancerCare #CommunityOncology #Nashville

🥁 62 advanced practice providers from OneOncology partner practices recently came together at JADPRO Live 2025, the national meeting of the Advanced Practice Society for Hematology and Oncology. 🩺 OneOncology and our partner practices presented six abstracts from five different partner practices, plus one from OneOncology – showcasing topics ranging from multidisciplinary care models and APP training programs to compensation models and rapid response initiatives. ⬇️ Read our blog post to learn about each Abstract. ⬇️ https://lnkd.in/ekfNRphX

🥁 Daniel Wakefield MD MPH will moderate a discussion with Dr. Todd Doyle and Casey Chollet-Lipscomb, MD, FASTRO dissecting trends in radiation oncology at the upcoming OneOncology Annual Conference. 🩺 The panel will touch on future technology developments, Medicare payment cuts, and the Radiation Oncology Case Rate Program, which is a bipartisan legislative initiative (S. 1031/H.R. 2120) designed to reverse disastrous Medicare Part B payment trends. 🎤 We’re looking forward to an insightful discussion. ⬇️ To learn more about the OneOncology meeting series, reach out to the Events team at Events@OneOncology.com. https://lnkd.in/dkkX-rhF

🧬 Solid vs Liquid Biopsy — Which Test, When, and Why It Matters Molecular testing has become routine in oncology — but one question keeps coming up: Should I order tissue NGS or a liquid biopsy? The answer, as always, is nuanced. 🔹 Tissue (solid) testing Still considered the gold standard for most solid tumors. It allows for: ✔️Comprehensive profiling: Detects SNVs, indels, CNVs, fusions, and complex alterations (e.g., MSI-H, TMB). ✔️Histology correlation: Integrates morphology, IHC, and genomics. ✔️Higher sensitivity for low-frequency variants in a well-preserved sample. Limitations: ✖️Tissue exhaustion (biopsy material may be limited) ✖️Turnaround time ✖️May not reflect tumor evolution or heterogeneity at progression 🔹 Liquid biopsy (cfDNA-based testing) A game changer when tissue is insufficient or inaccessible. It offers: ✔️Minimal invasiveness – just a blood draw ✔️Faster results – typically within days ✔️Dynamic monitoring – captures tumor evolution and emerging resistance Limitations: ✖️Sensitivity depends on tumor DNA shedding — false negatives can occur, especially in low-volume or CNS-only disease. ✖️Cannot detect fusions or CNVs as reliably as tissue-based platforms (though improving rapidly). ✖️No histopathologic context. 🧩 Practical takeaway: At diagnosis: Start with tissue when feasible. If tissue is inadequate or inaccessible: Add or reflex to liquid biopsy. At progression: Liquid biopsy can reveal resistance mutations and guide next-line therapy. 🧩 Ideal scenario: Use both — they are complementary, not competitive. As genomic assays expand, the smartest question is no longer “which test is better?” but “how can both work together to tell the complete story of the tumor?” #PrecisionOncology #MolecularTesting #NGS #LiquidBiopsy #CancerGenomics #OncologyInsights #ClinicalOncology #CancerDiagnostics